Medtronic's InPen smart insulin pen device kept patients in their target blood glucose range for longer periods of time compared to previous treatment without the pen, according to results presented at the 81st American Diabetes Association Scientific Sessions. The study analyzed patient data of 1,736 individuals between January 2018 and October 2020.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,